Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.

Cancer immunity - 17 Feb 2006

Schanzer Juergen M, Baeuerle Patrick A, Dreier Torsten, Kufer Peter

Abstract excerpt

Pro-inflammatory cytokines regulate the growth, differentiation, and activation of immune cells and can play a role in antitumor responses. GM-CSF and IL-2 induce tumor rejection in animal models when expressed by tumor cells, and IL-2 is used for the treatment of melanoma and renal cell cancer. However, high doses of GM-CSF and IL-2 are associated with severe side effects in cancer patients. We generated a dual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Drug Combinations

Share to Drug Delivery Systems

Share to Epithelial Cell Adhesion Molecule

Share to Granulocyte-Macrophage Colony-Stimulating Factor

Share to Interleukin-2

Source

Identifiers

PMID: 16483188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.PMID 16483188Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity Read ↗

Targeting human γδ T cells as a potent and safe alternative to pan-T cells bispecific cell engagersSemantic proximity Read ↗

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancerSemantic proximity Read ↗

Dual Immune Checkpoint and Cytokine Receptor Modulation by an Engineered Human CTLA-4/IL-10 Bispecific Fusion ProteinSemantic proximity Read ↗

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine ReceptorsSemantic proximity Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applicationsSemantic proximity Read ↗

A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor ActivitySemantic proximity Read ↗

Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacitySemantic proximity Read ↗

CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific AntibodiesSemantic proximity Read ↗

A compound chimeric antigen receptor strategy for targeting multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.